Dissertations / Theses on the topic 'Phlorizin'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 24 dissertations / theses for your research on the topic 'Phlorizin.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.
Collins, Alison Jane. "Ontogeny of lactase-phlorizin hydrolase in the pig small intestine." Thesis, University of Cambridge, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.388687.
Full textKeller, Patrick. "Developmental regulation and post-translational modification of lactase-phlorizin hydrolase and sucrase-isomaltase /." [S.l.] : [s.n.], 1994. http://e-collection.ethbib.ethz.ch/show?type=diss&nr=10881.
Full textHollox, Edward John. "Molecular and population genetic analyses of variation within and surrounding the human lactase gene." Thesis, University College London (University of London), 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.322742.
Full textBehrendt, Marc [Verfasser]. "Characterization of natural and artificial mutants of human intestinal lactase phlorizin hydrolase / Marc Behrendt." Hannover : Technische Informationsbibliothek und Universitätsbibliothek Hannover, 2010. http://d-nb.info/1010839373/34.
Full textMeier, Anja Doris [Verfasser], and Florian [Akademischer Betreuer] Lang. "Der Einfluss von Phlorizin auf den programmierten Zelltod von Erythrozyten / Anja Doris Meier ; Betreuer: Florian Lang." Tübingen : Universitätsbibliothek Tübingen, 2013. http://d-nb.info/1160754551/34.
Full textOenzil, Fadil, and mikewood@deakin edu au. "Effect of vitamin A deficiency on glucose uptake in the rat." Deakin University. School of Science, 1988. http://tux.lib.deakin.edu.au./adt-VDU/public/adt-VDU20051110.120816.
Full textMaekawa, Tatsuya. "Studies on mechanisms of peripheral and central neuropathy in Spontaneously Diabetic Torii (SDT) fatty rats." Kyoto University, 2019. http://hdl.handle.net/2433/242679.
Full text0048
新制・課程博士
博士(農学)
甲第21802号
農博第2315号
新制||農||1065(附属図書館)
学位論文||H31||N5174(農学部図書室)
京都大学大学院農学研究科応用生物科学専攻
(主査)教授 久米 新一, 教授 松井 徹, 教授 廣岡 博之
学位規則第4条第1項該当
Oberholzer, Thomas. "Subzelluläre Lokalisierung der proteolytischen Prozessierung der menschlichen Laktase-Phlorizin-Hydrolase und eine mögliche Rolle der Pro-Region im intrazellulären Transport /." [S.l.] : [s.n.], 1993. http://e-collection.ethbib.ethz.ch/show?type=diss&nr=10242.
Full textKatsuda, Yoshiaki. "Studies on kidney pathophysiological analyses in SDT fatty rat, a novel obese diabetic model." Kyoto University, 2015. http://hdl.handle.net/2433/202781.
Full text0048
新制・論文博士
博士(農学)
乙第12973号
論農博第2823号
新制||農||1037(附属図書館)
学位論文||H28||N4955(農学部図書室)
32411
新制||農||1037
(主査)教授 久米 新一, 教授 今井 裕, 教授 松井 徹
学位規則第4条第2項該当
Ma, Jinyu, and 马金余. "Phloretin and phloridzin as modulators in maillard reaction model systems." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2011. http://hub.hku.hk/bib/B47146977.
Full textRidgway, T. J. "The development of production methods for phloridzin-derived colourants and antioxidants." Thesis, University of Nottingham, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.339601.
Full textDionísio, Lília Maria Correia. "Inibidores do co-transportador renal de sódio-glicose 2: uma nova classe terapêutica para o controlo de glicemia na diabetes." Master's thesis, [s.n.], 2015. http://hdl.handle.net/10284/5174.
Full textA Diabetes Mellitus é uma patologia crónica considerada uma epidemia global. Atinge ambos os sexos, surge cada vez mais precocemente, e a sua prevalência está aumentada na obesidade e nos indivíduos com uma alimentação desequilibrada. A morbilidade e mortalidade associadas a esta doença, assim como o consequente impacto negativo quer nos doentes, quer na sociedade e na economia, fazem com que o controlo da Diabetes Mellitus seja apontado como um enorme desafio para a Saúde Pública Mundial. A terapêutica não farmacológica (que inclui programas de exercício físico e implementação de uma dieta saudável e equilibrada) é a base do tratamento da Diabetes Mellitus. No entanto, a maioria dos pacientes não atinge os objetivos terapêuticos apenas com estas medidas, havendo necessidade de recorrer adicionalmente à terapêutica farmacológica (agentes antidiabéticos orais e/ou insulinoterapia). Apesar de as terapêuticas farmacológicas existentes serem eficazes no controlo das glicemias, estas apresentam diversas limitações (risco de hipoglicemia, aumento de peso, efeitos gastrointestinais adversos e/ou retenção de fluídos) que condicionam a sua utilização. Por esse motivo, são necessários novos agentes terapêuticos com melhores perfis de risco-benefício, que possibilitem um melhor controlo glicémico e uma maior redução das complicações associadas à Diabetes Mellitus. Os inibidores do co-transportador sódio-glicose 2 (SGLT2) apresentam-se assim como uma alternativa terapêutica baseada num mecanismo de ação inovador, que pode ultrapassar algumas limitações da terapêutica já existente e contribuir para um melhor controlo desta epidemia. Com o presente trabalho, pode constatar-se que os inibidores do co-transportador de sódio-glicose 2 parecem ser uma solução terapêutica promissora, com um mecanismo de ação independente da insulina, com as vantagens da diminuição da hemoglobina glicada, diminuição da glicose em jejum e pós prandial, diminuição do peso, melhoria da hiperuricemia (se presente), redução da pressão sanguínea e prevenção de complicações micro e macrovasculares melhorando, deste modo, a qualidade de vida do doente e dos seus familiares. No entanto, apesar das expectativas depositadas nesta classe de fármacos, com o evoluir dos estudos constatou-se que estes também apresentam diversos efeitos adversos, tais como o aumento de infeções urinárias e genitais, aumento do colesterol total e LDL, desidratação, aumento da frequência e volume urinário e hipotensão postural. Diabetes Mellitus is a chronic pathology considered a global epidemy. This disease affects both men and women, now appears at earlier ages, and its prevalence is increased in obesity and in individuals with an unbalanced diet. Morbidity and mortality associated with this disease, as well as the consequent negative impact on patients, society and economy, make the control of Diabetes Mellitus a major challenge for the World Healthcare. Non-pharmacological treatment (which includes physical exercising programmes and implementation of a healthy and balanced diet) is the basis of Diabetes Mellitus' treatment. However, most patients do not reach the therapeutic goals using only these measures and need to resort to pharmacological therapies (oral antidiabetic agents and/or insulin). Although the existing drug therapies are effective in controlling blood glucose levels, they present several limitations (risk of hypoglycemia, weight gain, gastrointestinal side effects and/or fluid retention) that limit its use. Therefore, new therapeutic agents with improved risk-benefit profiles that enable a better glycemic control and reduce the complications associated with Diabetes Mellitus are needed. Sodium-glucose co-transporter 2 (SGLT2) inhibitors appear as an alternative therapeutic approach based on a different mechanism of action that may overcome some of the limitations of the existing therapeutic agents and contribute to a better control of this epidemy. In this work, the inhibitors of the sodium-glucose co-transporter 2 appear as a promising therapeutic solution, with a mechanism of action that is independent of insulin, with the advantages of decreasing the glycated haemoglobin, the fasting and postprandial blood glucose levels and weight, improving hyperuricemia (if present), decreasing blood pressure and preventing micro and macrovascular complications, therefore improving the life quality of the patient and his family. However, despite the expectations placed on this class of drugs, with the progress of the studies, it was found that these agents also have several adverse effects, such as the increase of urinary and genital infections, increase of total and LDL cholesterol, dehydration, increase of the frequency and urinary volume and postural hypotension.
Paripelly, Rammohan. "Molecular Level Interaction of Human Fibroblast Growth Factor-1 (hFGF-1) With Phloridzin." TopSCHOLAR®, 2013. http://digitalcommons.wku.edu/theses/1314.
Full textPayne, Jason N. "Development of Dihydrochalcone Functionalized Gold Nanoparticles for Augmented Antineoplastic Activity." TopSCHOLAR®, 2016. http://digitalcommons.wku.edu/theses/1749.
Full textDuluc, Isabelle. "Structure de la lactase-phlorizine hydrolase du rat et expression au cours du développement post-natal et le long du tractus intestinal." Aix-Marseille 3, 1992. http://www.theses.fr/1992AIX30092.
Full textPessoa, Thaíssa Dantas. "Modulação do trocador NA+/H+ apical, NHE3, pelo transporte de glicose em túbulos renais in vivo." Universidade de São Paulo, 2009. http://www.teses.usp.br/teses/disponiveis/42/42137/tde-01072009-122346/.
Full textWe studied the modulation of bicarbonate reabsorption by the apical Na+/H+ exchanger of renal proximal tubule by luminal glucose, and the signaling path of this relationship. Treatment with phloridzin and streptozotocin diabetes on HCO3- reabsorption was also studied. We used stationary microperfusion in vivo for this purpose. Tubule perfusions with 5 mM glucose increased bicarbonate reabsorption compared to solutions without glucose plus phloridzin. Perfusion with 20 mM glucose caused an intermediate effect on JHCO3- compared to 0/phloridzin and 5 mM glucose. The inhibitors PD169316 and LY294002 with 5 mM glucose blocked the stimulatory effect of the latter, but H89 had no such effect. Streptozotocin diabetes abolished the inhibitory effect of 20 mM glucose perfusion. Chronic phloridzin did not produce any additional effect on JHCO3- during 20 mM glucose perfusion in normal rats., but blocked JHCO3- during perfusion with 5 mM glucose.
Syzov, Vladyslav. "Delivery of a coated bioactive from a rumen controlled-release device." The University of Waikato, 2008. http://hdl.handle.net/10289/2368.
Full textOulianova, Natalia. "Évaluation du modèle dimérique de contransport Na§+-D-glucose pour l'interprétation des études cinétiques du transport de glucose et de la liaison de phlorizine sur vésicules de membrane à bordure en brosse isolées du cortex rénal de lapin." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1996. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp04/nq21499.pdf.
Full textLin, Chih-Cheng, and 林志成. "Human lactase-phlorizin hydrolase gene cloning and transgenic mice production." Thesis, 2001. http://ndltd.ncl.edu.tw/handle/76056445476896984159.
Full text國立中興大學
生物化學研究所
89
In the present study, we attempt to generate low-lactose milk in vivo by expressing a human lactase-phlorizin hydrolase in the mice mammary gland during lactation. To achieve this, we amplified a fragment of hLPH probe from Human Small Intestine Marathon-Ready cDNA and screened in Human Small Intestine 5’-STRETCH cDNA Library. After three-rounds screening, we identified a novel hLPH cDNA clone (hLPH-1), which containing a coding region homologous to published hLPH cDNA 1716 nt to 5122 nt, but which exon12, exon15, exon16, and exon17 were complete deletion, and a novel 3’-UTR sequence followed with exon14. The 3’-UTR sequence is different from published hLPH cDNA. We proposed that hLPH-1 is a product through hLPH gene alternative splicing. It maybe is a member of the LPH gene family. By deducing the novel 3’-UTR secondary structure, we could find which have stable secondary structure. So we proposed the novel 3’-UTR can protect hLPH-1 mRNA when translation. In order to understand what function hLPH-1 have, we constructed the novel hLPH-1 gene under the control of the promoter of the milk protein, α-lactalbumin, and then micro-injected into the pronuclei of mouse one-cell embryos to understand if hLPH-1 has lactase activity as LPH and to produce low-lactose milk of transgenic mice. Unfortunately, the hLPH-1 transgenic mice was not produced until now, so we still not know hLPH-1 gene has what biological function.
Peters, Karen [Verfasser]. "Identifizierung eines intramolekularen Chaperons in der intestinalen Laktase-Phlorizin-Hydrolase / vorgelegt von Karen Peters." 2002. http://d-nb.info/965607240/34.
Full textBÁRTOVÁ, Hedvika. "Mléčné výrobky se sníženým obsahem laktózy a jejich vyhodnocení." Master's thesis, 2019. http://www.nusl.cz/ntk/nusl-395200.
Full textHuang, Wen-Ching, and 黃文經. "Functional analysis of a novel identified extracellular lactase-phlorizin hydrolase(EC-LPH)gene from human intestine." Thesis, 2006. http://ndltd.ncl.edu.tw/handle/30296303640781848709.
Full text國立中興大學
生命科學系
93
Human intestinal lactase-phlorizin hydrolase (hLPH), a major lactose digestive enzyme in small intestine of newborn, is synthesized as a high-molecular-mass precursor comprising four tandemly repeated domain. During the maturation, the precursor protein was glycosylation, proteolytic cleavage and dimerization on the membrane. In the previously study, a novel hLPH gene with C-terminal truncated membrane anchorless form had been identified from Small Intestine cDNA library in Human Small Intestine cDNA library, so we defined the novel hLPH as hLPH1. The hLPH1 cDNA and a normal intact hLPH were transfected into CHO cell, individually, to compare their cellular location and lactase activity in vitro. The result showed that the C-terminal truncated hLPH1 exhibiting lactase activity in extracellular space using X-Fuc staining. To further validate the hLPH1 activity in vivo , the hLPH1 gene was constructed under α-lactalbumin promoter control to generate a mammary-specific expression transgenic mice model. Since lactose is the major sugar present in milk and is an important osmotic regulator of milk secretion. This transgenic mice model provided us a good hLPH1 functional assay system. Data showed that the hLPH1 protein has been detected secretion in mammary aloveli and tubules by IHC assay and LPH activity in X-Fuc staining. Therefore, the hLPH1 can be redefined as extracellular hLPH (EC-LPH). A part of lactose has been hydrolyzed to galactose and glucose in vivo in the transgenic milk by TLC analysis. The growth performance of transgenic mice compared with wild type ICR mice had significant difference in body weight (p<0.001) during lactation stage. Key words: lactase-phlorizin hydrolase, hypolactasia, transgenic mice, X-Fuc
Prachařová, Eva. "Purifikace florizinu z listů Malus domestica Borkh. extrakcí na pevné fázi a semipreparativní vysokoúčinnou kapalinovou chromatografií." Master's thesis, 2018. http://www.nusl.cz/ntk/nusl-387773.
Full textAouameur, Rym. "Caractérisation du co-transporteur Na+/myo-inositol SMIT2 dans les membranes en bordure en brosse de rein de lapin et d’intestin de rat." Thèse, 2009. http://hdl.handle.net/1866/2846.
Full textMyo-inositol (MI) is an organic solute involved in various aspects of cell physiology, including cell signaling. It is also known as a compatible osmolyte. Three secondary active MI cotransporters have been identified; two are Na+- coupled (SMIT1 and SMIT2) and one is H+-coupled (HMIT). The main aim of this study was to characterize MI uptake throught SMIT2 as expressed in epithelial cells and in Xenopus laevis oocytes. In order to achieve the characterization of this transport system, we used purified brush border membrane vesicles (BBMv) isolated from rabbit kidney and rat intestine. We first performed a quantification of mRNA levels in rabbit kidney using real time PCR for both SMIT1 and SMIT2. We found that SMIT1 is mainly expressed in the renal medulla while SMIT2 is mainly localized in the renal cortex. This result was confirmed on Western blots using an antibody raised against SMIT2. Through inhibition studies using selective substrates for SMIT1 (inhibited by L-fucose) and SMIT2 (inhibited by D-chiroinositol), we showed that SMIT2 seems to be responsible for all the apical transport of MI into the proximal convoluted tubule with a Km of 57 ± 14 µM. By transport studies we established that rabbit intestine seems to lack apical transport of MI while rat intestine has a very active uptake of this molecule. qRT-PCR quantification confirmed the absence of MI transporters in rabbit intestine. As for kidney, SMIT2 seems to be the only transporter responsible for apical MI uptake in enterocytes with a Km of 150 ± 40 µM. Functional analysis of rat SMIT2 activity, via electrophysiological studies in Xenopus oocytes, demonstrated similarities to the activities of SMIT2 from rat intestine and rabbit kidney. SMIT2 displays high affinities for MI (270 ± 19 µM), DCI (310 ± 60 µM) and no affinity for L-fucose. SMIT2 is very sensitive to phlorizin (Pz; 16 ± 7 µM). Although these functional characteristics essentially confirmed those found in rat intestine, a iv discrepancy exists between the two systems studied. Indeed, the affinity constant for glucose was approximately 40-fold lower in vesicles than in oocytes. We also tested the ability of SGLT1 and GLUT5, other sugar transport systems present in enterocytes apical membranes, to perform MI uptake. Because the inhibition of these transporters did not alter radiolabeled MI uptake, we concluded that they had no significant contribution to MI transport in rat intestine. Finally, the basolateral efflux of MI was not mediated by GLUT2 because when expressed in oocytes, this transporter was not able to transport MI.